ES2178854T3 - Bibliotecas de marcadores de afinidad para albumina de suero humano. - Google Patents
Bibliotecas de marcadores de afinidad para albumina de suero humano.Info
- Publication number
- ES2178854T3 ES2178854T3 ES98959387T ES98959387T ES2178854T3 ES 2178854 T3 ES2178854 T3 ES 2178854T3 ES 98959387 T ES98959387 T ES 98959387T ES 98959387 T ES98959387 T ES 98959387T ES 2178854 T3 ES2178854 T3 ES 2178854T3
- Authority
- ES
- Spain
- Prior art keywords
- albumin
- library
- affinity markers
- human soil
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000009027 Albumins Human genes 0.000 title 1
- 108010088751 Albumins Proteins 0.000 title 1
- 239000002689 soil Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuesto de la fórmula E-Ca-R-Cb-A, en la que E es un agente terapéutico o de diagnóstico, R es un grupo reactivo, Cb y Ca son un primer y un segundo grupos de conexión opcionales, respectivamente y A es un grupo de afinidad que comprende cualquier molécula o parte de una molécula que posea determinantes de unión específicos para una molécula diana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6470597P | 1997-11-07 | 1997-11-07 | |
US7792798P | 1998-03-13 | 1998-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2178854T3 true ES2178854T3 (es) | 2003-01-01 |
Family
ID=26744806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98959387T Expired - Lifetime ES2178854T3 (es) | 1997-11-07 | 1998-11-06 | Bibliotecas de marcadores de afinidad para albumina de suero humano. |
Country Status (8)
Country | Link |
---|---|
US (1) | US7166695B2 (es) |
EP (2) | EP2033661A1 (es) |
AT (2) | ATE406577T1 (es) |
AU (1) | AU1519699A (es) |
CA (2) | CA2305597C (es) |
DE (2) | DE69806066T2 (es) |
ES (1) | ES2178854T3 (es) |
WO (1) | WO1999024075A2 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60026300T2 (de) * | 1999-05-17 | 2006-11-16 | Conjuchem, Inc., Montreal | Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile |
US7144854B1 (en) | 1999-09-10 | 2006-12-05 | Conjuchem, Inc. | Long lasting anti-angiogenic peptides |
EA003922B1 (ru) | 1999-05-17 | 2003-10-30 | Конджачем, Инк. | Продолжительно действующие инсулинотропные пептиды |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
CA2373252C (en) * | 1999-05-17 | 2007-08-07 | Conjuchem Inc. | Long lasting anti-angiogenic peptides |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US20040266673A1 (en) * | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
CA2372338A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
US7090851B1 (en) | 1999-09-10 | 2006-08-15 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
EA006484B1 (ru) | 2001-02-02 | 2005-12-29 | Конджачем, Инк. | Долгоживущие производные рилизинг-фактора гормона роста |
WO2002066511A2 (en) | 2001-02-16 | 2002-08-29 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
ATE412667T1 (de) | 2001-05-31 | 2008-11-15 | Conjuchem Biotechnologies Inc | Langwirkende fusionspeptidinhibitoren gegen hiv- infektion |
DE602004027000D1 (de) | 2003-01-17 | 2010-06-17 | Advanced Proteome Therapeutics | Verfahren zur Identifizierung aktivierter Polymer-Komplexe zur sekundären Stellen-spezifischen Modifikation von Protein Ziel-Gruppen. |
DE602005014969D1 (de) * | 2004-04-23 | 2009-07-30 | Conjuchem Biotechnologies Inc | Verfahren zur aufreinigung von albumin-konjugaten |
WO2007053946A1 (en) * | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
MX2008008076A (es) * | 2005-12-22 | 2008-11-28 | Conjuchem Biotechnologies Inc | Procesos para la produccion de conjugados preformados de albumina y un agente terapeutico. |
US20090099074A1 (en) * | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
WO2009075859A2 (en) * | 2007-12-11 | 2009-06-18 | Conjuchem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
WO2017139329A1 (en) * | 2016-02-09 | 2017-08-17 | Alexander Krantz | Site-selective functionalization of proteins using traceless affinity lables |
EP3617235A4 (en) | 2017-04-28 | 2020-12-16 | Ajinomoto Co., Inc. | ASSOCIATION WITH A SUBSTANCE WITH AFFINITY TO SOLUBLE PROTEIN, FITTABLE PART AND REACTIVE GROUP OR SALT THEREOF |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3862928A (en) * | 1969-07-09 | 1975-01-28 | Akzona Inc | Psychopharmacological hexa-peptides containing a d-phenylalanyl residue |
US4244946A (en) | 1979-06-11 | 1981-01-13 | The Salk Institute For Biological Studies | Water-soluble peptides affecting gonadal function |
US4933288A (en) * | 1986-11-21 | 1990-06-12 | Cetus Corporation | Use of a modified soluble Pseudomonas exotoxin A in immunoconjugates |
US4808705A (en) * | 1986-12-19 | 1989-02-28 | Cetus Corporation | Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor |
GB8713240D0 (en) * | 1987-06-05 | 1987-07-08 | Proteus Biotech Ltd | Hormones |
US4981979A (en) * | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
DE3731297C1 (de) | 1987-09-17 | 1989-05-18 | Rexroth Mannesmann Gmbh | Schaltventilanordnung |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
ATE135045T1 (de) * | 1988-07-23 | 1996-03-15 | Delta Biotechnology Ltd | Sekretorische leader-sequenzen |
EP0440740B1 (en) * | 1988-10-12 | 1993-09-22 | Centocor, Inc. | Radiotherapeutic immunoconjugates labeled with iodine-125 |
US5250662A (en) * | 1989-10-05 | 1993-10-05 | Alpha Therapeutic Corporation | Albumin purification |
US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
US5182366A (en) | 1990-05-15 | 1993-01-26 | Huebner Verena D | Controlled synthesis of peptide mixtures using mixed resins |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US5612034A (en) | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
US5843440A (en) | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
JP3523252B2 (ja) | 1990-11-21 | 2004-04-26 | ホウテン ファーマシューティカルズ インコーポレイテッド | 等モル多種オリゴマー混合物、特にオリゴペプチド混合物の合成 |
US5616311A (en) * | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
WO1993006121A1 (en) | 1991-09-18 | 1993-04-01 | Affymax Technologies N.V. | Method of synthesizing diverse collections of oligomers |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
JPH0692968A (ja) * | 1992-09-16 | 1994-04-05 | Nakarai Tesuku Kk | ビオチン導入試薬 |
PL308204A1 (en) | 1992-09-24 | 1995-07-24 | Chiron Corp | Synthesis of n-substituted oligomers |
US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
US5741893A (en) * | 1993-08-16 | 1998-04-21 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5571681A (en) * | 1994-03-10 | 1996-11-05 | The Scripps Research Institute | Chemical event selection by suicide substrate conjugates |
JP2000502897A (ja) | 1995-12-18 | 2000-03-14 | プレーシス ファーマスーティカルズ インコーポレイテッド | 標的に結合する化合物を同定する方法 |
EP0814850A1 (en) * | 1996-01-12 | 1998-01-07 | Redcell Canada Inc. | Cellular and serum protein anchors for diagnostic imaging |
US6277583B1 (en) * | 1996-02-07 | 2001-08-21 | Conjuchem, Inc. | Affinity labeling libraries and applications thereof |
US5840733A (en) | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
AU4351897A (en) | 1996-09-16 | 1998-04-02 | Conjuchem, Inc. | Affinity labeling libraries with tagged leaving groups |
US6203820B1 (en) * | 1998-05-28 | 2001-03-20 | Brice E. Vickery | Compositions and methods for enhancing protein anabolism and detoxification |
-
1998
- 1998-11-06 AT AT01126379T patent/ATE406577T1/de not_active IP Right Cessation
- 1998-11-06 DE DE69806066T patent/DE69806066T2/de not_active Expired - Lifetime
- 1998-11-06 WO PCT/US1998/023705 patent/WO1999024075A2/en active IP Right Grant
- 1998-11-06 AT AT98959387T patent/ATE218892T1/de active
- 1998-11-06 EP EP08162256A patent/EP2033661A1/en not_active Withdrawn
- 1998-11-06 EP EP98959387A patent/EP1056474B1/en not_active Expired - Lifetime
- 1998-11-06 ES ES98959387T patent/ES2178854T3/es not_active Expired - Lifetime
- 1998-11-06 AU AU15196/99A patent/AU1519699A/en not_active Abandoned
- 1998-11-06 CA CA002305597A patent/CA2305597C/en not_active Expired - Fee Related
- 1998-11-06 DE DE69839946T patent/DE69839946D1/de not_active Expired - Fee Related
- 1998-11-06 CA CA002628053A patent/CA2628053A1/en not_active Abandoned
-
2004
- 2004-09-02 US US10/934,841 patent/US7166695B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7166695B2 (en) | 2007-01-23 |
US20050037974A1 (en) | 2005-02-17 |
CA2628053A1 (en) | 1999-05-20 |
DE69839946D1 (de) | 2008-10-09 |
AU1519699A (en) | 1999-05-31 |
DE69806066T2 (de) | 2003-02-06 |
EP1056474B1 (en) | 2002-06-12 |
CA2305597A1 (en) | 1999-05-20 |
ATE406577T1 (de) | 2008-09-15 |
CA2305597C (en) | 2008-07-29 |
WO1999024075A2 (en) | 1999-05-20 |
EP1056474A2 (en) | 2000-12-06 |
ATE218892T1 (de) | 2002-06-15 |
WO1999024075A3 (en) | 1999-09-02 |
EP2033661A1 (en) | 2009-03-11 |
DE69806066D1 (de) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2178854T3 (es) | Bibliotecas de marcadores de afinidad para albumina de suero humano. | |
CA2204535A1 (en) | Molecules that home to a selected organ or tissue in vivo and methods of identifying same | |
IL138717A0 (en) | A method for identifying small molecule drug lead compounds | |
CA2265484A1 (en) | Tumor homing molecules, conjugates derived therefrom, and methods of using same | |
DE69834596D1 (de) | Etectrochirurghische, blutstillende klammervorrichtung | |
ES2141128T3 (es) | Combinacion de agentes anti-hormonales y moleculas de fijacion. | |
NO950651L (no) | Antitranspirasjonsdeodorantpreparat | |
ATE375362T1 (de) | Von cyclophilin b abstammende tumorantigen- peptide | |
AU2987695A (en) | Interruption of binding of mdm2 and p53 protein and therapeutic application thereof | |
EA200100111A1 (ru) | Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами | |
ATE211135T1 (de) | Aminocyclohexylester und ihre anwendung | |
MX9603570A (es) | Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos. | |
WO2000018439A3 (de) | Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren | |
FI940375A (fi) | Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa | |
PT1071433E (pt) | 2',2'-difluoronuecleosidos para terapia imunossupressora e preparados farmaceuticos combinados | |
BR9201253A (pt) | Composto,processo para a sua preparacao,agente diagnostico ou terapeutico e aplicacao do mencionado composto | |
ES2187972T3 (es) | Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes. | |
ES2118481T3 (es) | Procedimiento para la obtencion de 2-halogenopiridinaldehidos. | |
ES2171018T3 (es) | Uso de agentes inmunomoduladores. | |
DE69627702D1 (de) | Stabilisierte, korrosionsinhibierte feuerhemmende zusammensetzungen und methoden | |
ATE489971T1 (de) | Ionaustausch-tumor zielausrichtung | |
ID23794A (id) | Proses, pembuatan dan penggunaan garam bentuk (2r, 3r) tartrat | |
BR0014192A (pt) | Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores | |
BR0110111A (pt) | Derivados de ácido poliamidanucléico, agentes e processos para a sua preparação | |
EA199901061A1 (ru) | Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии |